Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease

Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease

Despite being studied in clinical trials, CETP inhibitors are not yet an approved treatment for coronary heart disease. Here, by analyzing results from clinical trials and drug target mendelian randomization studies, the authors demonstrate that previous failure of CETP inhibitors are likely compoun...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Amand F. Schmidt, Nicholas B. Hunt, Maria Gordillo-Marañón, Pimphen Charoen, Fotios Drenos, Mika Kivimaki, Deborah A. Lawlor, Claudia Giambartolomei, Olia Papacosta, Nishi Chaturvedi, Joshua C. Bis, Christopher J. O’Donnell, Goya Wannamethee, Andrew Wong, Jackie F. Price, Alun D. Hughes, Tom R. Gaunt, Nora Franceschini, Dennis O. Mook-Kanamori, Magdalena Zwierzyna, Reecha Sofat, Aroon D. Hingorani, Chris Finan
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/60544e33b7ec4a46bdebdd316f81bb1d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Despite being studied in clinical trials, CETP inhibitors are not yet an approved treatment for coronary heart disease. Here, by analyzing results from clinical trials and drug target mendelian randomization studies, the authors demonstrate that previous failure of CETP inhibitors are likely compound and not drug target-related.

Ejemplares similares